Anti-IL-1 β therapies

Recent Patents on DNA and Gene Sequences

Volumn 5, Issue 2, 2011, Pages 126-135

  Zhang, Hong ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Antibody; IL 1 ; IL 1 receptor antagonists; IL 1 trap; Inflammasome; Inflammatory disease

Indexed keywords

ADAPTOR PROTEIN; CANAKINUMAB; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CRYOPYRIN; CYT013 IL1BQB; CYTOKINE RECEPTOR ANTAGONIST; GEVOKIZUMAB; IMMUNOLOGIC AGENT; INFLAMMASOME; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT INTRACELLULAR ISOFORM; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT SECRETED ISOFORM; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA ANTIBODY; MEVALONATE KINASE; PATTERN RECOGNITION RECEPTOR; PLACEBO; PROTEIN; PROTEIN CARD8; PYRIN; RANIBIZUMAB; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; TALMAPIMOD; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG; VALSARTAN;

ACUTE HEART INFARCTION; ADULT ONSET STILL DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANTIINFLAMMATORY ACTIVITY; ARTICLE; AUTOIMMUNE DISEASE; AUTOSOMAL DOMINANT INHERITANCE; AUTOSOMAL RECESSIVE INHERITANCE; BEHCET DISEASE; BLEPHARITIS; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CINCA SYNDROME; CLINICAL TRIAL (TOPIC); CORNEA NEOVASCULARIZATION; CORONARY ARTERY DISEASE; CRYOPYRINOPATHY; CYTOKINE RELEASE; DRUG APPROVAL; FAMILIAL COLD AUTOINFLAMMATORY SYNDROME; FAMILIAL MEDITERRANEAN FEVER; FATIGUE; GENETIC DISORDER; GLUCOSE INTOLERANCE; GOUT; HEART FAILURE; HUMAN; HYPERTENSION; IMMUNE SYSTEM; IMMUNOPATHOGENESIS; INFLAMMATORY DISEASE; INNATE IMMUNITY; INSULIN DEPENDENT DIABETES MELLITUS; JUVENILE RHEUMATOID ARTHRITIS; KIDNEY FAILURE; KNEE INJURY; MUCKLE WELLS SYNDROME; MULTIPLE MYELOMA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PLASMACYTOMA; POSTERIOR BLEPHARITIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; RETINA MACULA CYSTOID EDEMA; RHEUMATOID ARTHRITIS; SCHNITZLER SYNDROME; SIGNAL TRANSDUCTION; SJOEGREN SYNDROME; SOLID TUMOR; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; UVEITIC CYSTOID MACULAR EDEMA;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; HUMANS; INTERLEUKIN-1BETA; PATENTS AS TOPIC; RECOMBINANT FUSION PROTEINS;

EID: 79960023037     PISSN: 18722156     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221511796392024     Document Type: Article

References (77)

1. Medzhitov RC, Janeway Jr. Innate immunity. N Engl J Med 2000; 343: 338-44.
2. Sun JC, Lopez-Verges S, Kim CC, Derisi JL, Lanier LL. NK cells and immune "memory". J Immunol 2011; 186: 1891-7.
3. Schroder K, Tschopp J. The inflammasomes. Cell 2010; 140: 821-32.
4. Beg AA. Endogenous ligands of Toll-like receptors: implications for regulating inflammatory and immune responses. Trends Immunol 2002; 23: 509-12.
5. Matzinger P. The danger model: a renewed sense of self. Science 2002; 296: 301-5.
6. Mogensen TH. Pathogen recognition and inflammatory signaling in innate immune defenses. Clin Microbiol Rev 2009; 22: 240-73.
7. Casanova JL, Abel L, Quintana-Murci L. Human TLRs and IL-1Rs in host defense: natural insights from evolutionary, epidemiological, and clinical genetics. Annu Rev Immunol 2011; 29: 447-91.
8. Yoneyama MM, Kikuchi T, Natsukawa N, et al. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol 2004; 5: 730-7.
9. Kanneganti TD, Lamkanfi M, Nunez G. Intracellular NOD-like receptors in host defense and disease. Immunity 2007; 27: 549-59.
10. Takaoka AZ, Wang MK, Choi H, et al. DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. Nature 2007; 448: 501-5.
11. Hornung VA, Ablasser M, Charrel-Dennis F, et al. AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. Nature 2009; 458: 514-8.
12. Akira SS, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006; 124: 783-801.
13. Wilmanski JM, Petnicki-Ocwieja T, Kobayashi KS. NLR proteins: integral members of innate immunity and mediators of inflammatory diseases. J Leukoc Biol 2008; 83: 13-30.
14. Kanneganti TD, Lamkanfi M, Nunez G. Intracellular NOD-like receptors in host defense and disease. Immunity 2007; 27: 549-59.
15. van de Veerdonk FL, Netea MG, Dinarello CA, Joosten LA. Inflammasome activation and IL-1β and IL-18 processing during infection. Trends Immunol 2011; 32: 110-6.
16. Verstrepen L, Bekaert T, Chau TL, Tavernier J, Chariot A, Beyaert R. TLR-4, IL-1R and TNF-R signaling to NF-kappaB: variations on a common theme. Cell Mol Life Sci 2008 65: 2964-78.
17. Zhang H, Fu W. NDPP1 is a novel CARD domain containing protein which can inhibit apoptosis and suppress NF-kappaB activation. Int J Oncol 2002; 20: 1035-40.
18. Bouchier-Hayes L, Conroy H, Egan H, et al. CARDINAL, a novel caspase recruitment domain protein, is an inhibitor of multiple NFkappa B activation pathways. J Biol Chem 2001; 276: 44069-77.
19. Pathan N, Marusawa H, Krajewska M, et al. TUCAN, an antiapoptotic caspase-associated recruitment domain family protein overexpressed in cancer. J Biol Chem 2001; 276: 32220-9.
20. Agostini F, Martinon K, Burns EM, et al. NALP3 forms an IL-1b processing inflammasome with increased activity in Muckle-Wells auto-inflammatory disorder. Immunity 2004; 20: 319-25.
21. Razmara M, Srinivasula SM, Wang L, et al. CARD-8 protein, a new CARD family member that regulates caspase-1 activation and apoptosis. J Biol Chem 2002; 277: 13952-8.
22. von Kampen O, Lipinski S, Till A, et al. Caspase recruitment domain-containing protein 8 (CARD8) negatively regulates NOD2-mediated signaling. J Biol Chem 2010; 285: 19921-6.
23. Schreiber S, Nikolaus S, Hampe J, et al. Tumour necrosis factor alpha and interleukin 1beta in relapse of Crohn's disease. Lancet 1999; 353: 459-61.
24. Yang SK, Kim H, Hong M, et al. Association of Card8 with inflammatory bowel disease in Koreans. J Hum Genet 2011; 56: 217-23.
25. Roberts RL, Topless RK, Phipps-Green AJ, Gearry RB, Barclay ML, Merriman TR. Evidence of interaction of CARD8 rs2043211 with NALP3 rs35829419 in Crohn's disease. Genes Immun 2010; 11: 351-6.
26. Fontalba A, Martinez-Taboada V, Gutierrez O, et al. Deficiency of the NF-kappaB inhibitor caspase activating recruitment domain 8 in patients with rheumatoid arthritis is associated with disease severity. J Immunol 2007; 179: 4867-73.
27. Schoultz I, Verma D, Halfvarsson J, et al. Combined polymorphisms in genes encoding the inflammasome components NALP3 and CARD8 confer susceptibility to Crohn's disease in Swedish men. Am J Gastroenterol 2009; 104(5): 1180-8.
28. Kastbom A, Johansson M, Verma D, Söderkvist P, Rantapää-Dahlqvist S. CARD8 p. C10X polymorphism is associated with inflammatory activity in early rheumatoid arthritis. Ann Rheum Dis 2010; 69: 723-6.
29. Fontalba A, Gutiérrez O, Llorca J, Mateo IJ. Deficiency of CARD8 is associated with increased Alzheimer's disease risk in women. Dement Geriatr Cogn Disord 2008; 26: 247-50.
30. Fontalba A, Gutiérrez O, Llorca J. Gene-gene interaction between CARD8 and interleukin-6 reduces Alzheimer's disease risk. J Neurol 2009; 256: 1184-6.
31. Liu J, Liu X, Dai L, Wang G. Recent progress in elucidating the structure, function and evolution of disease resistance genes in plants. J Genet Genomics 2007; 34: 765-76.
32. Arend WP, Palmer G, Gabay C. IL-1, IL-18, and IL-33 families of cytokines. Immunol Rev 2008; 223: 20-38.
33. Steinkasserer A, Spurr NK, Cox S, Jeggo P, Sim RB. The human IL-1 receptor antagonist gene (IL1RN) maps to chromosome 2q14-q21, in the region of the IL-1 alpha and IL-1 beta loci. Genomics 1992; 13: 654-7.
34. Patterson D, Jones C, Hart I, et al. The human interleukin-1 receptor antagonist (IL1RN) gene is located in the chromosome 2q14 region. Genomics 1993; 15: 173-6.
35. Dinarello CA. The interleukin-1 family: 10 years of discovery. FASEB J 1994; 8: 1314-25.
36. Villanueva-Mendoza C, Arellanes-García L, Cubas-Lorenzo V, Jimenez-Martinez MC, Flores-Suárez LF, Zenteno JC. Familial case of Blau syndrome associated with a CARD15/NOD2 mutation. Ophthalmic Genet 2010; 31: 155-8.
37. Hoffman HM, Mueller JL, Broide DH, Wanderer AA, Kolodner RD. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet 2001; 29: 301-5.
38. Tunca M, Ozdogan H. Molecular and genetic characteristics of hereditary autoinflammatory diseases. Curr Drug Targets Inflamm Allergy 2005; 4: 77-80.
39. Shohat M, Halpern GJ. Familial mediterranean fever-A review. Genet Med 2011 Feb 23.
40. Houten SM, Romeijn GJ, Koster J, et al. Identification and characterization of three novel missense mutations in mevalonate kinase cDNA causing mevalonic aciduria, a disorder of isoprene biosynthesis. Hum Mol Genet 1999; 8: 1523-8.
41. Houten SM, Kuis W, Duran M, et al. Poll-The BT. Mutations in MVK, encoding mevalonate kinase, cause hyperimmunoglobulinaemia D and periodic fever syndrome. Nat Genet 1999; 22: 175-7.
42. Aksentijevich I, Masters SL, Ferguson PJ, et al. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med 2009; 360(23): 2426-37.
43. So A, De Meulemeester M, Pikhlak A, et al. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study. Arthritis Rheum 2010; 62: 3064-76.
44. Zhou R, Tardivel A, Thorens B, et al. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol 2010; 11: 136-40.
45. Gasse P, Riteau N, Charron S, et al. Uric acid is a danger signal activating NALP3 inflammasome in lung injury inflammation and fibrosis. Am J Respir Crit Care Med 2009, 179: 903-13.
46. Dostert C, Petrilli V, Van Bruggen R, et al.: Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 2008; 320: 674-7.
47. van der Meer JW, Simon A. Blocking IL-1beta to slow down progression of ALS? Proc Natl Acad Sci USA 2010; 107: 12741-2.
48. Meissner F, Molawi K, Zychlinsky A. Mutant superoxide dismutase 1-induced IL-1beta accelerates ALS pathogenesis. Proc Natl Acad Sci USA 2010; 107: 13046-50.
49. Hwang MW, Matsumori A, Furukawa Y, et al. Neutralization of interleukin-1beta in the acute phase of myocardial infarction promotes the progression of left ventricular remodeling. J Am Coll Cardiol 2001; 38: 1546-53.
50. Stenvinkel P. The role of inflammation in the anaemia of end-stage renal disease. Nephrol Dial Transplant 2001; 16: 36-40.
51. Pizzirani C, Falzoni S, Govoni M, et al. Dysfunctional inflammasome in Schnitzler's syndrome. Rheumatology (Oxford) 2009; 48: 1304-8.
52. Dickinson CD, Alain PV, Jeffry DW, Lu J. Humanized anti-IL-1 beta antibodies. US7714120, 2010.
53. Hermann G, Thomas J. Indications for Anti-IL-1 Beta therapy. US20100166750, 2010.
54. Masat L, Haak-Frendscho M, Chen G, Horwitz A, Roell M. Method of treating an IL-1 related inflammatory disease or condition. US7,695,717, 2010.
55. Solinger AM, Patrick J, Scannon RJ. BauerMethods for the treatment of IL-1.beta. related diseases. US7,695,718, 2010.
56. Hsieh C-M, Mcrae BL, Kutskova Y, et al. Dual-specific IL-1A/IL-1b antibodies. US20090291081, 2009.
57. Masat L, Haak-Frendscho M, Chen G, Horwitz A, Roell M. IL-1.beta. binding antibodies and binding fragments thereof. US7,744,866, 2010.
58. Hasty K. Kanangat S, Postlethwait A. Intracellular interleukin-1 receptor antagonists. US7,674,464, 2010.
59. Donath M. Use of an interleukin 1 receptor antagonist and/or pyrrolidinedithiocarbamate for the treatment or prophylaxis of type 2 diabetes. US7,572,770, 2009.
60. Green L, Raffaella F, Orit F, Klakamp SL, Senaldi G, Schneider AK. Antibodies against interleukin-1.beta. US7,566,772, 2009.
61. Hermann G, Franco EDiP. Antibodies to human IL-1.beta. US7,491,39217, 2009.
62. Zhou C, Shen W, Martin FH. Methods for identifying functional antibodies. US7,884,054, 2011.
63. Lawson A, Andrew GP. Antibody molecules having specificity for human IL-1.beta. US7,608,694, 2009.
64. Stahl N, Yancopoulos GD. IL-1 receptor based cytokine traps and method of using. US7,417,134, 2008.
65. Mellis S, Stahl N, Radin A, et al. Use of an IL-1 antagonist for treating arthritis. US7, 361,350, 2008.
66. Bednarik D, Olsen HS, Rosen CA, et al. Soluble interleukin-1 receptor accessory molecule. US7,390,880, 2008.
67. Vicary C, Mellis S. Use of IL-1 antagonists to treat gout. US7,820,154, 2010.
68. Batchelor MJ, David B, Bemis GW, et al. Inhibitors of interleukin-1.beta. converting enzyme. US7,790,713, 2010.
69. Goldsmith DP. Periodic fever syndromes pediatrics in review. Pediatrics Rev 2009; 30: e34-e41.
70. Larsen CM, Faulenbach M, Vaag A, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007; 356: 1517-26.
71. Lust JA, Lacy MQ, Zeldenrust SR, et al. Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1β-induced interleukin 6 production and the myeloma proliferative component. Mayo Clin Proc 2009; 84: 114-22.
72. Abbate A, Kontos MC, Grizzard JD, et al. VCU-ART investigators. Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction. Am J Cardiol 2010; 105: 1371-7.
73. Chevalier X, Goupille P, Beaulieu AD, et al. Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2009; 61: 344-52.
74. Hoffman HM, Throne ML, Amar NJ, et al. Efficacy and safety of rilonacept (interleukin-1 TRAP) in patients with cryopyrinassociated periodic syndromes: results from two sequential placebocontrolled studies. Arthritis Rheum 2008, 58: 2443-52.
75. Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, et al. Canakinumab in CAPS study group. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 2009; 360: 2416-25.
76. Kummer JA, Broekhuizen R, Everett H, et al. Inflammasome components NALP 1 and 3 show distinct but separate expression profiles in human tissues suggesting a site-specific role in the inflammatory response. J Histochem Cytochem 2007; 55(5): 443-52.
77. Novick D, Dinarello C, Menachem R, et al. Interleukin-18 binding proteins, their preparation and use for the treatment of sepsis. US7704944, 2010.